{"name":"Topaz Pharmaceuticals Inc","slug":"topaz-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Placebo, vehicle control","genericName":"Placebo, vehicle control","slug":"placebo-vehicle-control","indication":"Clinical trial control (not a therapeutic indication)","status":"marketed"}]}],"pipeline":[{"name":"Placebo, vehicle control","genericName":"Placebo, vehicle control","slug":"placebo-vehicle-control","phase":"marketed","mechanism":"Placebo has no active pharmacological mechanism and serves as an inert control to establish baseline disease progression and assess non-specific treatment effects.","indications":["Clinical trial control (not a therapeutic indication)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4AJBVV95cUxQUVZCaWcyX2dmUDBDV3dPRXAzcjh5dlhyYjV2NTA1SFhCSWxCcGx1R1lLS2lkdXZUTmk5MVo5bkZaMlEyZ2NSdU1JTWcxY1N0UUh5UWdUOWx0a3lTQVRzUnM4NVVQb3dZODhwa2lRS05iRkpncEZGX3VxSEVPcWRNdklaQWxkVnEwZDgtNm9vOU1BWlRhY3R0Vm9HNklZNE84ZFRodjl1NzV3NzVzYlVDWk5WcmNLVTVEY3FreDNRSTFPSVYzZjNRYlE2dlRLaDhzOHBiODFXZWtKMzlIMFV5WW85eEtCYThZV252SXVhZkt1Y0JteU5MWHpael9qdGpqRGh0N2pjYXAxaTFzajFhMlowYThwTlkyQjlyOVpUV3ZXN1JFbF94RXBhd2cyelhXZmIzRHh4bll2NVZ1bml1RTMwN0lwY0trcXRtUU5JYnR3cWNoZlcyNk5nZFVxVFZn?oc=5","date":"2026-04-06","type":"pipeline","source":"Finansavisen","summary":"Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, Deadline - Contact Kessler Topaz Meltzer & Check, LLP - Finansavisen","headline":"Ultragenyx Pharmaceutical Inc. (RARE) Class Action Lawsuit Seeks Recovery for Investors; April 6, 2026, Deadline - Conta","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxQd0pMcDBRTlZTMm1LUVhSU2FSZG5SWmktd0szMnAzbEdxdWdNcG13N2R1NTd0aUs1Q185RWFVbXVhaV84djJlR0V6cFphZXFzSkdwLVlydEItQ2NTdEdhY2YzS3NKcXVsUV85QmhpNlVaemIzQ0dSY1BfOUN6YWc1NUtScndabzlweDh5RXhYVjdLejFiV0J1ck9ZcVp4aGVzM1FBcjljSktueWdwRzRpaEN3aEdMT0hTcVpwMHZObHhFYTJRbjVLVzBIUDJmVVFQT0phNTU3UzhjSU9FY1lnd2h6SkEtWDVMaWtlZmhtTnNqZ2ltZjRXbVVJS1FjVzdnb3pRSGFJSWIteVRGeENldnRkMS05dw?oc=5","date":"2026-03-29","type":"pipeline","source":"FinancialContent","summary":"SLNO Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages SLNO Investors With Losses to Contact the Firm - FinancialContent","headline":"SLNO Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages SLNO Investors With Losses to Contact the Firm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxPYXU3ZlZZNEk1enlJTVRWNkRweU9tbW1jdjFPTF9ER3NvdjBXWnBsbkk5X2t6V2djNkJvSlBWVERzZnhvSUY1ZWtiaU9zZDEydGV2djJWNDlKU1VLYkd6NE04UGVCdjRiUHJDVVppakMycmdOQ3RYVUVLSjJqRF92dFlvRXBRa0NsZS1TTGZiMjdNS00?oc=5","date":"2026-01-13","type":"regulatory","source":"Yahoo Finance","summary":"Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to Rising Use of Biologics – Approvals of BENLYSTA and SAPHNELO, Plus a Strong Pipe","headline":"Systemic Lupus Erythematosus Market to Exhibit Growth at a CAGR of 9.4% During the Forecast Period (2025–2034) Owing to ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPZnRZNHZQYndqaHpwV3dVZkNwSUFnVkUtNHppSDZNd3cwdzhFeUhWQzZIVWg2OWVxTVlIbEJqdWgzcDZVVnR5eHcxM1M1V1VTYmM5c0Qyd0ZjWmJMT19DT1pOWHhHRUdpSUdWVzI5bTRzVl9KQ0VqRF9mcnUxa3lTM0pFYTJKNVVzcFUzRg?oc=5","date":"2024-06-12","type":"deal","source":"Contract Pharma","summary":"Ono Acquires Deciphera Pharmaceuticals - Contract Pharma","headline":"Ono Acquires Deciphera Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxPRE4ycFliWEtBcDhWVFZpenZ1dnp1ZVUyWXVseE9kczhIZXVnWXhsa1RKY3pEZzc5NE5ncVdoRjZLTkJVaE9RdHltQXdVM25EWUphM0pRRlpuNU5NN2xKYThtQXVvTHp4SUwzamhleGdCRFRNMUhEYm9RNmg4LS1KMW91N3pXSk1DN2hjNHNZY2N0XzZvb082Y1RaV3drN2xPVEdwZUpmT3V1eDdzUDNMVDlpWWpudUNIMmwzeVpjSHJvdkd0V0FjZDNFTk1qS1o4NHIxSE5qbVdqOEJOMURVWTJxR0tXaG1kUkpScWlPbGpBOFdLTkU0Z2pVWllxYjU3TkJZU3F3?oc=5","date":"2024-06-11","type":"deal","source":"BioSpace","summary":"Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono) - BioSpace","headline":"Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNaGFRMHFFVlBvMWJDa2x0b1Fzb0FiVTBMVDFWem52YWRIS3V1a0RnUnQ4V0hpU2QtMTdMLTAyOC02LWV5dWd2NzZzNDlMTkhXRmxvazhVMUY4SERoV2E0YmxmNFBhR1J1N3BxNDN2anpSYXVfZlZXQXZYcW9OY2loMTVITDlZeW1GMEpibTg2TmNDaGVYX2ZLNjlqZk1leWR1ekE?oc=5","date":"2024-01-31","type":"deal","source":"Contract Pharma","summary":"Pharmaceutical Industry Mergers & Acquisitions Roundup - Contract Pharma","headline":"Pharmaceutical Industry Mergers & Acquisitions Roundup","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-01-22","type":"pipeline","source":"IANS","summary":"Indo-Asian News Service - IANS","headline":"Indo-Asian News Service","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBHeXBURHNxck5YQ1B1a2JFS1RXLTNoVDF4UlFQX1B6MU5NWThDQ0FSejNiUmxSYWhiRjFJb2w0eGxiTVp3dWJyQXlIdFVrUUVjd3lBY2VQdC1Hc2xKUmlr?oc=5","date":"2021-03-01","type":"trial","source":"Nature","summary":"The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism - Nature","headline":"The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgJBVV95cUxOR3NwYzh6RThaSmtobzJDbXdyRzBtYmFaM3pJQTB5ZlZKZ3ZaOENOTm5VWExpRXdyeWZvam42c0todUgxZU9kdFczTGtnVnFNMTNyYjEyRFNkVWd4bVZRQzgzNm9VbzhVdjYtaXAzTG94TDZ1bGZZbmhKWDNFVWhGWEVkMVhJQm1ZYkJkdzhfMmpBWDN1Zlo2V3dFSC1Hc0ZpQ1JoN3REbFVrb1FReW9KWEZDakYtdXNWV1NnM21Cdk9mTHZqcnFWcFRTRVYzOWhNbmpXOFFlYXdxVmcyaGdMUEpqcy1ZRHVMU29GYkJ5T1NmTWlOYV9BbHdScER5ZWlMekJpSGVzSW9EZklGSEcySmRiemIya2ppNDlXOWx5dFl0VmllUjZFWmZB?oc=5","date":"2019-08-06","type":"pipeline","source":"marketscreener.com","summary":"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Acer Therapeutics, Inc. – ACER - marketscreener.com","headline":"Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Acer Therape","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}